AFT Pharmaceuticals Limited (ASX:AFP)

Market Cap	305.34M
Revenue (ttm)	189.03M
Net Income (ttm)	10.87M
Shares Out	n/a
EPS (ttm)	0.10
PE Ratio	28.09
Forward PE	21.20
Dividend	0.02 (0.59%)
Ex-Dividend Date	Jun 18, 2025

Volume	8,322
Average Volume	3,530
Open	2.700
Previous Close	2.590
Day's Range	2.700 - 2.840
52-Week Range	2.150 - 2.990
Beta	0.29
RSI	84.72
Earnings Date	Nov 21, 2025

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 119
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AFP

Financial Performance

In 2024, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.

Financial numbers in NZD